Advance Auto Parts stock sinks toward 12-year low after credit cut to 'junk' status at S&P Global Ratings
Shares of Advance Auto Parts Inc. (AAP) dropped 3.7% toward a 12-year low in morning trading Tuesday, after S&P Global Ratings downgraded the auto parts retailer's credit to "junk" status, saying the company's efforts to improve inventory and product availability have "languished" due to inconsistent execution. The credit rating agency cut the company's issuer-credit rating to BB+, which is the highest speculative-grade rating, from BBB-, while revising the outlook to stable from negative. S&P also criticized the company for its "misguided strategic decision" to try to preserve and expand margins while its competitors cut prices. "Over the past eighteen months, Advance's sales have largely been flat, while its peers' revenues have grown in a low-teen percent," S&P said in a research note. "We believe Advance has ceded market share and its competitive standing in the industry has weakened." The stock, which is on track for its lowest close since October 2011, has tumbled 59.0% year to date. In comparison, shares of rivals AutoZone Inc. (AZO) have gained 3.8% this year and of O'Reilly Automotive Inc. (ORLY) have gained 10.7%, while the S&P 500 has advanced 16.6%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-12-23 1007ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
What the Fed’s QT Program Is, and Why Its End Matters
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?